Every growing biotech eventually faces the question: do we build this ourselves or buy it? Someone on the team is always confident they could build a better system than the expensive one on offer, and sometimes they are right. But in biotech the calculation is different from most industries, because regulated software carries a validation burden that changes the economics entirely. The default answer in biotech is buy, and the exceptions are narrow but real. Here is a framework for deciding.
Why validation changes the math
The thing that makes biotech different is that software touching regulated processes, clinical data, quality systems, manufacturing records, must be validated and maintained in a validated state, with documentation that will survive inspection. That burden is substantial and ongoing: it applies not just to the initial build but to every update, every change, forever. Commercial vendors amortize that cost across many customers and have built the documentation, processes, and expertise to sustain it. A biotech building its own regulated system takes on that entire burden alone, permanently, with a team whose actual job is developing drugs. This single factor tips most regulated software decisions decisively toward buying.
When buying is clearly right
Buy when the software supports a standard, well-served function where good commercial options exist and your needs are not genuinely unusual. This covers most of what a biotech needs: clinical data capture, regulatory information management, quality management, safety, laboratory information management, and electronic notebooks. In these categories, mature validated products exist, the vendors carry the compliance burden, and your requirements are almost certainly less unique than you think. Buy also when the function is not a source of competitive advantage, since building something that does not differentiate you is a poor use of scarce engineering talent, and when speed matters, because buying is almost always faster than building.
When building can make sense
Building is defensible in a few situations. When the software is your competitive advantage, which is genuinely true for companies whose science is computational, a platform biotech’s discovery engine is not something you buy, it is what you are. When your needs are genuinely unusual and no commercial product fits, though be honest here, since “our workflow is unique” is usually less true than teams believe. When the software sits outside the regulated space, such as internal research tooling, where the validation burden does not apply and the calculus resembles ordinary software decisions. And when you need integration glue between systems you have bought, which is often best built in-house and is a legitimate and common case.
The hidden costs of building
Teams consistently underestimate what building costs. Beyond initial development there is ongoing maintenance, which never ends and consumes engineering capacity indefinitely. There is validation and revalidation for anything regulated, a permanent tax. There is key-person risk, since the person who built it will eventually leave and the system becomes an orphan nobody understands. There is the opportunity cost of engineers not working on your actual science. And there is the upgrade trap, where the system slowly falls behind and you eventually have to buy a commercial product anyway, having spent years and considerable money to arrive where you would have started.
A practical framework
Ask four questions in order. First, is this software a source of genuine competitive advantage? If yes, consider building. If no, lean strongly toward buying. Second, is it regulated? If yes, the validation burden makes buying substantially more attractive unless the first answer was an emphatic yes. Third, does a mature commercial option genuinely fit? Be honest, and test your assumption that your needs are unique. Fourth, do you have the engineering capacity to build and maintain this forever, not just build it once? If any of these points toward buying, buy. A hybrid approach, buying the platforms and building the integrations and the genuinely differentiated pieces on top, is often the right answer in practice.
The bottom line
In biotech, buy by default and build by exception. The validation burden on regulated software, the permanence of maintenance, and the opportunity cost of engineers not advancing your science all argue strongly for buying the standard platforms your industry has already built. Build where software genuinely is your competitive advantage, where your needs truly are unusual, or where you need to connect systems together. Be skeptical of the confident engineer who says they could build it better, not because they could not, but because building it is rarely the question, and maintaining it forever, validated, is.
The hybrid approach most companies land on
In practice, the build-versus-buy question is rarely answered purely one way, and the pattern most mature biotechs converge on is worth describing, because it tends to be the sensible destination. They buy the platforms: the validated, regulated systems that handle clinical data, quality, regulatory information, safety, and laboratory management, because these are well served commercially, carry a heavy compliance burden, and offer no competitive advantage. They build the differentiated layer: the computational tools, models, and analyses that constitute their actual scientific edge, because that is what makes them a company rather than a customer. And they build the connective tissue: the integrations, data pipelines, and internal tools that link purchased systems together and make the whole estate usable, because vendors rarely connect their products to one another as well as you need, and this glue is both genuinely custom and usually outside the regulated boundary. This pattern works because it puts engineering effort where it creates value and buys where the market has already solved the problem better than you will. The discipline it requires is honesty about which category a given piece of software falls into, and specifically resisting the temptation to classify something as differentiated when it is really just a standard function you would rather build than buy. A useful test: if a competitor could purchase a comparable capability off the shelf, it is not your competitive advantage, and you should probably buy it too. Applied consistently, this framing keeps your engineers on the work that matters and keeps your regulated systems in the hands of vendors whose job it is to maintain them.
The bottom line, restated
Build versus buy in biotech is asymmetric in a way it is not in most industries, because the validation burden on regulated software is permanent and heavy while the commercial market has already solved most standard problems well. Buy the platforms, build what genuinely differentiates you, build the glue that connects them, and be rigorously honest about which category any given piece of software actually falls into. Apply the test consistently: if a competitor could buy a comparable capability off the shelf, it is not your advantage, and your engineers have better things to do than rebuild it.
Be honest about the unique-workflow claim
The most common justification for building is that a company’s needs are too unusual for any commercial product, and the most common truth is that they are not. Workflows feel unique from the inside because you know their details intimately, but the underlying functions, tracking samples, capturing data, managing documents, are shared across an entire industry that has built products for exactly them. Before accepting the uniqueness argument, ask what specifically cannot be accommodated, whether it could be handled by configuration, and whether the process itself might sensibly change. Very often the answer is that the workflow is not unique, merely familiar.
To find and compare software platforms serving biotech, browse the BioMed Nexus digital health and biotech SaaS directory, and see our overview of digital health and biotech SaaS platforms.
Frequently asked questions
Should a biotech build or buy software?
Buy by default and build by exception. Software touching regulated processes must be validated and maintained in a validated state forever, a burden commercial vendors amortize across many customers. Building is defensible when the software genuinely is your competitive advantage, when needs are truly unusual, when it sits outside the regulated space, or for integration glue between purchased systems.
Why does validation make building software harder in biotech?
Because software touching regulated processes such as clinical data, quality systems or manufacturing records must be validated and kept in a validated state, with documentation that survives inspection. That burden applies not just to the initial build but to every update, permanently. A biotech building its own regulated system carries that entire burden alone with a team whose real job is developing drugs.
What are the hidden costs of building biotech software?
Ongoing maintenance that never ends and consumes engineering capacity indefinitely, validation and revalidation for anything regulated, key-person risk when the builder leaves and the system becomes an orphan, the opportunity cost of engineers not advancing the science, and the upgrade trap where the system falls behind and you buy a commercial product anyway after years of spending.
